Articles related to HYPERTENSION/BLOOD PRESSURE

In two randomized phase‑3 trials, a single‑pill triple low‑dose antihypertensive combination achieved blood pressure reductions comparable to amlodipine and superior to losartan monotherapy over 8 weeks.

Sdamlo’s FDA approval offers a new oral solution option for delivering amlodipine, addressing administration challenges in patients who cannot tolerate tablets.

Baxdrostat significantly reduced seated systolic blood pressure compared to placebo in 796 patients, with placebo-adjusted reductions of 9.8 mmHg and 8.7 mmHg at the 2 mg and 1 mg doses respectively, without impacting cortisol levels.

A year‑in‑review article highlights major cardiovascular themes from 2025, including evolving approaches to hypertension, myocardial infarction management, and atrial fibrillation care.

Magnesium supplementation has been studied for blood pressure control, yet evidence remains mixed and effects appear modest and context‑dependent.

Small studies suggest NMN supplementation may slightly affect blood pressure, but observed changes are modest and far less impactful than established therapies.